Optic Neuropathy, Ischemic Clinical Trial
Official title:
Retrobulbar Triamcinolone Acetonide Injection in the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy
NAION produces an ischemic insult in the optic nerve head presumably due to the
hypoperfusion of the short ciliary arteries that supply it.
Intravenous injection of glucocorticoid have proven to be effective in treatment of
Nonarteritic Anterior Ischemic Optic Neuropathy,but have some side effects. the
investigators believe that offering them Retrobulbar Triamcinolone Acetonide Injection that
might halt the progression of the visual acuity and visual field loss if our hypothesis is
correct, would greatly improve their chances of avoiding blindness.
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00759174 -
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
|
||
| Not yet recruiting |
NCT05749094 -
Optic Nerve Sheath Ultrasound in Giant Cell Arteritis
|
||
| Withdrawn |
NCT01607671 -
Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%
|
Phase 1 | |
| Completed |
NCT00404729 -
Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases
|
Phase 4 |